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doi:10.1016/j.fjs.2011.11.002Summary The human liver consists of three types of liver cells: mature hepatocytes, cholan-
giocytes, and bipolar adult hepatic stem/progenitor cells (HPC). These three types of cell are
commonly regarded as the primary targets of malignant transformation in the liver, if exposed
to carcinogens in vivo or in vitro. Activation and proliferation of hepatic progenitor cells have
been reported in precancerous conditions, such as chronic inflammation (hepatitis B/hepatitis
C, alcoholic hepatitis and steatohepatitis). An origin of hepatocellular carcinoma (HCC) from
hepatic progenitor cells is currently inferred from the fact that many tumors contain a mixture
of mature cells and cells phenotypically similar to hepatic progenitor cells. In our series, there
were 42 patients (31 males, 11 females, aged 23e80 years old) with HCC, who accepted liver
resection, yielding specimens sufficient for pathological studies. Immunohistochemical studies
were made with human monoclonal antibodies against OV-6, CD133, CK-19, CD44, AFP for
investigating the HPC. HPC grading was higher in HCC patients with hepatitis B or hepatitis
C and lower in those with non-B or non-C hepatitis. As regards the survival of HCC patients
based on the grading of cancer stem cells (CSC) within the tumor, the group of Grade 0 showed
a more favorable survival rate than that of Grade 1e3. The 1-, 3-, and 5-year survival rates of
Grade 0 and Grade 1e3 were 92%, 76%, and 69%, and 63%, 50%, and 50%, respectively
(pZ 0.073). These liver CSC would be more resistant to chemotherapeutic agents than tumor
cells with limited proliferative potential. In conclusion, we strongly believe that the contribu-
tions of HPC warrant research in patients with HCC. Without determining the characteristics of
CSC, it is impossible to propose new treatment strategies.
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206 C.-G. Ker et al.1. IntroductionFigure 1 Schema of Duct of Haering and niches of HPC.Hepatocellular carcinoma (HCC) is commonly found in
Taiwan and its prognosis is unsatisfactory with surgical or
non-surgical treatment modalities. Hepatic stem cells are
indefinite as cells that have the ability to perpetuate
themselves through self-renewal and to differentiate into
mature cells by multiple signaling pathways. Histologically,
the human liver consisted of three types of liver cells:
mature hepatocytes, cholangiocytes, and bipolar adult
hepatic stem/progenitor cells (HPC). These three types of
cell are commonly regarded as the primary targets of
malignant transformation in the liver if exposed to carcin-
ogens in vivo or in vitro. The most important and useful
property of stem cells is that of self-renewal.1,2 HPC are
responsible for the regeneration of hepatocytes or chol-
angiocytes when the liver is injured. Because of this char-
acteristic, striking parallels can be found between stem
cells and cancer cells which may regulate self-renewal.
However, cancer cells may include cancer stem cells
(CSC) with indefinite potential for self-renewal, that
initiate tumorigenesis. The mechanisms directing the
transformation of stem cells to CSC and HCC remain to be
elucidated. The goal of the current studies is to apply such
insight to clinical medicine and to develop a better classi-
fication system of liver cancer.
The existence of CSC in solid tumors was first reported in
2003, and it was stated that such a small number of cells as
CD44þCD24-/low lineage cells from human breast cancer
tumors were able to initiate new tumors.3 More recently,
highly tumorigenic cells with distinct surface marker
phenotypes were indentified in tumors of the GI tract4e6
and other solid tumors.3,7,8 Similarly, liver cancer/progen-
itor cells in HCC have been identified in previous
reports.9e11 In a study by Zhu et al,11 CD133þ cancer cells
possessed stem cell properties, including higher prolifera-
tive potential, greater colony-forming efficiency, self-
renewal and differentiating capacity than CD133e cells.
Therefore, a set of surface molecule markers could more
accurately define the cancer stem cell subpopulation
responsible for the initiation and progression of HCC.12,13
2. Defining features of liver progenitor cells
Four possible hepatic stem cells are identified in the canal
of Haering (proximal biliary tree): intralobular bile ducts,
periductal “null” mononuclear cells, and peribiliary
hepatocytes14 as shown in Fig. 1. Experimental induction
of liver stem/progenitor cells in rodents has been exten-
sively studied in liver chemical injury models and carci-
nogenesis. The application of a variety of experimental
protocols in animal models resulted in activation and
proliferation of adult liver stem/progenitor cells, often
referred to as oval cells. Oval cells are putative liver stem/
progenitor cells and were first described by Opie15 in 1944,
and later by Farber16 in 1956. Activation and proliferation
of hepatic progenitor cells have been reported in precan-
cerous conditions, such as chronic inflammation (hepatitis
B/hepatitis C, alcoholic hepatitis and steatohepatitis).17,18
Therefore, HPC could be a source of cancer stem cells in
HCC.3. What are the cancer stem cells?
CSC within a solid tumor give rise to various differentiated
tumor cells, and ultimately drive tumor growth and metas-
tasis. The modern tools of stem cell biology have provided
strong evidence to show that CSC arise from both normal
stem cells and from non self-renewing progenitor cells.19
Importantly, the term “cancer stem cell” is an operative
definition that does not necessarily have a developmental
relationship to normal stem cells, but a subset of cells within
a tumor can self-renew and elaborate tumor heteroge-
neity.20 Ultimately, the definition depends on the assays of
self-renewal and tumorigenicity. Some aggressive tumors
may have a high percentage of CSC, and chemotherapeutic
treatments may increase the frequency of CSC in a tumor
because of the non-stem cancer cells killed by chemo
agents.21,22 In addition, sub-clones of CSC will develop into
tumorigenic and non-tumorigenic progeny.23,24 These
results suggest that activation of oncogenic pathways in
a cellular background of genetic instability, coupled with an
inherent ability to self-renew, is involved in the acquisition
of metastatic behavior in the CSC population of tumors
derived from pluripotent cells.
4. Clinical implication of liver cancer stem cells
in hepatocellular carcinoma
HCC could be derived from either the putative periportal
stem cells or from the transition duct cells or their progeny
(hepatic genitor cells or oval cells). Recent reports have
shown that CD133þ cells have stem cell characteristics in
HCC as well as in other tumors.25,26 Therefore, we con-
ducted a study to investigate HPC in HCC and their clinical
significances. In our department, there were 42 patients
(31 males, 11 females, aged 23e80 years old) with HCC,
who accepted liver resection and yielded specimens which
were sufficient for pathological studies from 2004 to 2007.
Immunohistochemical studies were carried out with human
monoclonal antibodies against OV-6, CD133, CK-19, CD44
Table 1 Reaction of HPC in HCC with hepatitis B/hepatitis C.
Hepatitis B
(n Z 18)
Hepatitis C
(n Z 15)
Hepatitis
B þ C
(n Z 1)
Non-B þ C
hepatitis
(n Z 8)
Total
(n Z 42)
Mean age 54.50 65.07 65.00 59.50 59.48
Sex M 17 (94.4%) 9 (60.0%) 1 (100%) 4 (50.0%) 31 (73.8%)
F 1 (5.6%) 6 (40.0%) 0 4 (50.0%) 11 (26.2%)
OV-6-n  1 5 (27.8%) 5 (33.3%) 1 (100%) 1 (12.5%) 12 (28.6%)
OV-6-t  1 5 (27.8%) 2 (13.3%) 1 (100%) 1 (12.5%) 8 (19.0%)
P-n  1 9 (50.0%) 11 (73.3%) 0 4 (50.0%) 24 (57.1%)
P-t  1 6 (33.3%) 4 (28.6%) 0 5 (62.5%) 15 (36.6%)
AFP
(mean  SD)
20975.04 
83967.29
201.26 
330.90
33.10 1024.90 
2877.73
9257.19 
55049.21
AFP-n  1 7 (38.9%) 4 (26.7%) 0 1 (12.5%) 12 (28.6%)
AFP-t  1 6 (33.3%) 4 (26.7%) 0 3 (37.5%) 13 (31.0%)
Survival (M)
(mean  SD)
41.89 
19.18
32.47 
20.21
34.00 35.63  21.55 37.14  19.74
Liver cancer stem cells 207and AFP to investigate HPC in the tumors of HCC patients.
The number of HPC cells was counted at 100 magnifica-
tion under light microscopic examination. The following
definitions were used: Grade 0, normal or <25; Grade 1,
<25e50; Grade 2, 50e75; Grade 3, >75/field of 100
magnification. Clinical data and its relation with HPC were
studied and biostatistical analysis was performed (Table 1).
The difference was deemed significant if p value was
<0.05. The results are as follows: (1) the architecture of
the compartment between hepatocytes and bile ducts
including the three cell types, the terminal bile duct cells,
transition duct cells and the putative peri-portal liver stem
cells, are shown in Figs. 1e3. These cells have been
implicated as possibly giving rise to HCC; (2) HGC and
hepatitis B and hepatitis C e HPC grading was higher in
patients with HCC and hepatitis B or hepatitis C than in
those with non-B or C hepatitis, as shown in Fig. 4. The
higher incidence of HCC in hepatitis B infection is most
probably related to the increased turnover of hepatocytesFigure 2 Duct of Haering (arrow) located at non-tumor part
and liver progenitor cell (OV-6, 200).secondary to destruction of hepatocytes, leading to stim-
ulation of proliferation of stem cells and other progeny
early in the hepatocyte de-differentiation proliferation; (3)
liver CSC could be identified and showed positive staining
with CD133 or OV-6 within the liver cancer tissue, as shown
in Fig. 5. The CD133þ cells were round in shape and smaller
than malignant cells. The 1-, 3-, and 5-year survival rates
for Grade 0 and Grades 1e3 were: 92%, 76%, and 69%, and
63%, 50%, and 50%, respectively (p Z 0.073). The survival
rates (Tables 2 and 3) were different due to the various
gradings of CSC (Table 4), and the survival rate was better
in the group of Grade 0 than that in Grades 1e3, with a non-
significant difference as shown in Fig. 6.5. Discussion
Although the CSC model has existed for over 50 years, only
recently have the techniques of modern stem cell biologyFigure 3 Hepatic progenitor cell(short arrow) and newly
formed hepatocytes(OV-6, 400).
Figure 4 Rate of grading of CSC in the non-tumor and tumor
part with hepatitis B/hepatitis C.
Table 2 Survival rate according to the severity of HPC in
the non-tumor part of HCC.
n 1-y
death
1-y (%) 3-y
death
3-y (%) 5-y
death
5-y (%)
(A) OV-6, non-
tumor
Grade 0
30 3 90.00 7 75.79 7 75.79
Grade 1e3 12 3 75.00 5 58.33 6 43.75
(B) OV-6, tumor
Group 0 34 3 91.18 8 75.70 9 69.39
Group 1e3 8 3 62.50 4 50.00 4 50.00
Log Rank Test: (A) p Z 0.104; (B) p Z 0.073.
208 C.-G. Ker et al.begun to facilitate rapid progress in this field. It had been
demonstrated formally that a single cell can generate
a heterogenous cancer and self-renew by the isolated pure
tumorigenic cancer stem cells. As pointed out earlier,17,19
and also in our present results, etiological factors, such as
inflammation and viral hepatitis B and C, appear to
contribute to the development of HCC by creating pheno-
typically altered hepatocytes or hepatic progenitor cells. A
more recently proposed hepatic progenitor cell model for
HCC tumorigenesis may provide a personalized approach for
mentioning diagnosis and treatment strategies in these
patients. HCC could be derived from progenitor cells or de-
differentiated transformed cells, based on the observation
that embryonic stem cells and CSC have similar biological
behavior. Depending on the extent of genetic alteration, the
tumor cells may remain benign or become malignant and
even show metastatic potential. This could explain the
heterogenicity in HCC morphology, clinical behavior and
molecular profiles for tumorigenesis,27 as shown in Fig. 7.
Therefore, the HCC tumor initiated by a multistep carcino-
genesis event and by resulting in heterogenity in morphology
with stem cells of positive specific phenotypes, appears to
have the capability to be more aggressive.28
Concerning clinical implications of CSC, HCC expresses
some de-differentiation markers in the fetal liver, such asFigure 5 Liver cancer stem cells (arrows) scattered within
the tumor of hepatocellular carcinoma (CD133 stain, 400).AFP, CD133 or OV-6 (expression) in poorer prognoses.29,30 In
fact, a small population of CD133þ cells could be present in
hepatoblastoma as well as in HCC, suggesting the possibility
of stem cell origin in both.31 In a report by Yeh et al,32 the
survival analysis indicated that both CD133 and p53
expression in HCC predict poor disease-free survival
(pZ 0.009 and 0.001), whereas the presence of only CD133
expression predicted poor overall survival (pZ 0.001). The
Cox proportional hazard model showed that p53 and CD133
expression were two independent predictors for disease-
free survival. However, the severity of the inflammatory
infiltrate in chronic viral hepatitis is correlated with the
activation and localization of hepatic progenitor cells.32,33
Therefore, the confliction of the results of CD133 was
correlated with the presence or absence of hepatitis in
previous reports.32,34,35 However, the severity of CD133þ
was more strongly expressed in the presence of both
hepatitis B and hepatitis C in our studies. The survival rate
was worsened by the presence of CD133 in the tumor or
non-tumor part in HCC patients, such as OV-6 and CK19
(unpublished data).
In Taiwan, the majority of HCC patients are causatively
associated with hepatitis B/C virus infection with cirrhosis.
Liver stem cells may play an important role in liver regen-
eration, and are indented to have accumulating mutations
on these progenitor cells, resulting in malignant trans-
formation. The role of progenitor cells in hepatocarcino-
genesis is exemplified by chronic hepatitis, advanced liver
diseases, and non-alcoholic fatty liver diseases.34 In our
study, about 29% (12/42) and 19% (8/42) of our HCC
patients, in non-tumor and tumor part, respectively, have
positive expression of one or more markers of progenitor
cells such as alfa-fetoprotein, OV-6, CD133 and CK-19. This
expression profile can be the result of the acquisition ofTable 3 Survival rate according to the severity of HPC in
the tumor part of HCC.
OV6-tumor n 1-y
death
1-y (%) 3-y
death
3-y (%) 5-y
death
5-y (%)
Group 0 34 3 91.18 8 75.70 9 69.39
Group 1e3 8 3 62.50 4 50.00 4 50.00
Log Rank Test: p Z 0.073.
Table 4 Grading according to the gender of HCC.
Sex OV6-n OV6-t
0 1 2 3 0 1 2 3
Male 19 (63.33%) 10 (100%) 1 (100%) 1 (100%) 24(%) 5 (83.33%) 1 (100%) 1 (100%)
Female 11 (36.67%) 0 0 0 10(%) 1 (16.67%) 0 0
Total 30 (71.43%) 10 (23.81%) 1 (2.38%) 1 (2.38%) 34 (80.95%) 6 (14.29%) 1 (2.38%) 1 (2.38%)
Liver cancer stem cells 209progenitor cell markers during malignant transformation,
through either the manner of the de-differentiation
hypothesis in matured hepatocytes, or the maturation-
arrest hypothesis in progenitor cells. If the maturation-
arrest hypothesis is correct, and the malignant cells result
from gene mutations during maturation from progenitor
cells, these HCC precursors should express progenitor cell
features histopathologically, as shown in our series.
If the growth of HCC was driven by liver CSC, it would
have profound implications on cancer therapy. All pheno-
typically diverse cancer cells are treated as though they
have unlimited proliferative potential and would acquire
the ability to metastasize. However, a small number of
disseminated cancer cells can be detected at sites distant
from primary tumors in patients that never manifest
a metastatic status.36,37 These disseminated, circulating
cancer cells will possibly either be killed by the host
immune surveillance system, or lack the ability to form
a new metastatic tumor. If HCC stem cells can be identified
prospectively and isolated, we should be able to identify,
more efficiently, new diagnostic markers and therapeutic
targets expressed by the liver stem cells. Therefore, we can
explain the failure to develop chemotherapies that can
consistently eradicate HCC. Although currently available
drugs, including chemotherapeutic agents, or agents in
target therapies, can shrink metastatic HCC or other
metastatic lesions, these effects are usually transient and
often do not appreciably prolong the life of patients.25 One
reason for the failure of these treatments is the acquisition
of drug resistance by the cancer cells. Another possibility is
that existing therapies fail to effectively kill cancer stemFigure 6 Survival rate of HCC patients based on the grading
of CSC within the tumor part and more favorable survival rate
in the group of Grade 0 than in Grades 1e3 (Log Rank test,
p Z 0.073).cells. Normal stem cells, from various tissues, tend to be
more resistant to chemotherapeutic agents than mature
cell types from the same tissues.38 This may be due to high
levels of expression of anti-apoptotic proteins or ABC
transporters, such as the multidrug resistance gene.36,38
These liver CSC would be more resistant to chemotherapy
than tumor cells with limited proliferative potential. In our
un-published data, positive-staining ABC transporters were
rich in recognized liver CSC, as shown by tissue immuno-
histological staining. Liver CSC are more specifically
directed against chemotherapy or radiotherapy and the
tumor might pare enough cancer stem cells to allow
regrowth of the tumor, or so-called recurrence, as shown in
Fig. 7. The overall long-term survival of patients with HCC is
poor, because in most, HCC is concomitant with chronic
liver diseases. Therefore, for HCC patients at all stages,
there is a need for prognostic and predictive biomarkers
that can aid in the sub-classification of these tumors and
help to identify patients in each group who are most likely
to respond appropriately to available treatment modality.
In conclusion, self-renewal is the hallmark property of
stem cells in normal hepatocytes and HCC. Hepatocytes or
cholangiocytes contain self-renewing stem cells, and steps
in progression to HCC probably also occur in stem cells.Figure 7 HCC tumorigenesis based on the cancer stem cells
model. Liver cancer stem cells can arise from the hepatic stem
cells, hepatic progenitor cells or hepatocytes, as a conse-
quence of exposure to various risk factors such as HBV, HCV,
aflatoxin and alcohol. In addition, cancer stem cells are resis-
tant to the chemo/radiation therapy and might contribute to
recurrence caused by the hepatic cancer stem cells, still alive
after treatment.
210 C.-G. Ker et al.Liver cancer tumors may be mixed with HPC within cancer
tissue that can renew indefinitely and become different
from most stem cells that have limited proliferative
potential. In order to cure cancer, it is necessary to kill
a sufficient amount of CSC. The survival rates and recur-
rence rates in HCC, related with HPC, are worth investi-
gating. The contributions of HPC warrant research in
patients with HCC. Without investigation of these charac-
teristics of CSC, it would be difficult, if not impossible, to
propose new treatment strategies for our patients.
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